Bristol-Myers Squibb Company
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Bristol-Myers Squibb Company (NYSE: BMY), a global biopharmaceutical company headquartered in Princeton, New Jersey with roots tracing to mergers of entities founded in 1858 and 1887, discovers, develops, manufactures, and commercializes innovative medicines for serious diseases including cancer, immunology, cardiovascular, hematology, and neuroscience disorders; its primary products include the anticoagulant Eliquis (apixaban), oncology therapies such as Opdivo (nivolumab), Yervoy, Krazati, and Revlimid (lenalidomide), cell therapies Abecma and Breyanzi, immunomodulators like Orencia and Pomalyst, legacy brands such as Abraxane, Camzyos for hypertrophic cardiomyopathy, Cobenfy in neuroscience, and others including Baraclude, IDHIFA, Inrebic, Nulojix, Opdivo Qvantig, Reblozyl, and Thalidomid; the company operates in more than 120 countries with a focus on oncology, hematology, immunology, cardiovascular, and fibrotic diseases targeting patients with high unmet needs. In recent developments, Bristol-Myers Squibb completes the acquisition of Orbital Therapeutics in 2025 to strengthen its cell therapy portfolio with RNA medicines reprogramming the immune system; it forms a joint venture with Bain Capital in July 2025 for innovative immunology therapies and enters a global strategic partnership with BioNTech in June 2025 to co-develop and co-commercialize next-generation bispecific antibody BNT327 for multiple solid tumors; earlier, the company acquires 2seventy bio in March 2025 for full control of Abecma amid competitive pressures, completes acquisitions of Karuna Therapeutics in March 2024 to bolster neuroscience, RayzeBio in February 2024 for actinium-based radiopharmaceuticals, and Mirati Therapeutics in January 2024 to diversify oncology, alongside a $380 million capacity agreement with Cellares in April 2024 for CAR T manufacturing.
Company News
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services
2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now
This Popular Healthcare ETF Is Diluting Your Dividend Income
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
232,697 Shares in Bristol Myers Squibb Company $BMY Acquired by Beacon Pointe Advisors LLC
Bank OZK Invests $474,000 in Bristol Myers Squibb Company $BMY
Ancora Advisors LLC Takes $1.39 Million Position in Bristol Myers Squibb Company $BMY
Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
3 Dividend Stocks to Hold for the Next 10 Years
Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares
JP Morgan Warns of Fall Sell-Off Potential: 5 Defensive Dividend Stocks to Buy
42,000 Shares in Bristol Myers Squibb Company $BMY Acquired by Barbara Oil Co.
Blue Capital Inc. Purchases Shares of 18,381 Bristol Myers Squibb Company $BMY